miR-330-3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4.

MicroRNAs (miRNAs) serve as crucial regulators in the development of various cancers. Studies have mentioned that miR-330-3p is reduced in Acute myeloid leukemia (AML). Our research objectives included determining the regulatory roles and underlying mechanisms of miR-330-3p in AML progression. miR-330-3p expression in AML was quantified through qRT-PCR. The clinical relevance of miR-330-3p in AML progression, diagnosis, and prognosis was assessed by chi-square, ROC, Cox, and Kaplan-Meier survival analysis. The impacts of miR-330-3p on AML cell function were examined by CCK8 and Transwell assay. The targeting relationship between miR-330-3p and SYTL4 was analyzed via database and luciferase assay. miR-330-3p was obviously reduced in AML. Low miR-330-3p expression was related to adverse clinical features of AML, suggesting AML progression. miR-330-3p performed well in differentiating AML patients from healthy individuals, and reduced miR-330-3p expression was significantly related to poorer survival outcomes in patients with AML. miR-330-3p upregulation potently inhibited AML cell proliferation, migration, and invasion. Furthermore, SYTL4 was a target gene of miR-330-3p. And rescue tests demonstrated that miR-330-3p and SYTL4 jointly participate in the development of AML. In conclusion, miR-330-3p inhibited the development of AML by targeting SYTL4; miR-330-3p may serve as a valuable prognosis and diagnostic biomarker for AML patients.